Blood sugar self-monitoring in non-insulin treated type 2 diabetes doesn’t improve control
Trial shows no benefits to glycaemic control or health-related quality of life in patients who self-monitor glucose levels.
It has been debated whether self-monitoring blood glucose (SMBG) levels has any value in improving glycaemic control for patients with type 2 diabetes not requiring insulin. Despite this, more than 75% of these patients report doing so regularly.
In a year-long study published in JAMA Internal Medicine (online, 10 June 2017), researchers assigned 450 patients with non-insulin treated diabetes across 15 primary care practices to either once-daily SMBG, once-daily SMBG with tailored feedback via messaging or no SMBG at all.
At the end of the study, the researchers found no significant differences in HbA1c levels, a marker of recent glycaemic control, across the groups. There were also no differences in health-related quality of life.
The researchers say that SMBG should not be routine for patients with non-insulin treated type 2 diabetes and that clinicians should consider it on a case-by-case basis for individual patients.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20203053
Recommended from Pharmaceutical Press
Pharmacy Registration Assessment Questions 3 is the third volume in a series that follows on from the previous, highly popular Pharmacy Registration Assessment Questions 2. It features more than 400 entirely new, closed book and calculation questions. It can be used in conjunction with the previous volume or on its own.£35.00Buy now